OTC erythromycin
This article was originally published in The Tan Sheet
Executive Summary
FDA's Dermatologic Drugs and Anti-Infective Drugs Advisory Committees are scheduled to meet jointly on Nov. 16 to examine the potential for the development of antibiotic resistance if topical erythromycin were to be made available OTC for the treatment of acne. Originally scheduled for Sept. 23, the meeting was postponed to allow more time to find speakers, according to FDA